Takeda Pharmaceutical has signed licensing agreements with both Cipla and Sun Pharmaceutical to commercialize the gastrointestinal drug Vonoprazan in India. Cipla and Sun Pharma will market the drug under the brand name 'Voltapraz' in dosages of 10 mg and 20 mg. The agreements are non-exclusive, allowing both companies to distribute the drug in the Indian market. The announcement was made through an exchange filing.
Japan's Takeda Pharmaceutical gave India's Sun Pharmaceutical and Cipla the rights to commercialize gastrointestinal drug Vonoprazan in the country. https://t.co/89yhkBgL1Y https://t.co/89yhkBgL1Y
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India https://t.co/7nl13Iz7Es https://t.co/gmmwwsz7n2
#SunPharma in non-exclusive patent licensing pact with #TakedaPharma to commercialise Vonoprazan tablets in India: Exchange filing
#SunPharma enters into a non-exclusive patent licensing agreement with Takeda Pharmaceutical to commercialise gastro drug Vonoprazan 10 mg, 20 mg in India under the brand name “Voltapraz”
#JustIN | #SunPharma enters into a non-exclusive patent licensing agreement with Takeda Pharmaceutical to commercialise gastro drug Vonoprazan 10 mg, 20 mg in India under the brand name “Voltapraz” https://t.co/yZH1yEbHoH
News Alert | Cipla signs licence pact with Takeda for Vonoprazan in India @Cipla_Global https://t.co/kzEUWGp56Q